Non-invasive in vivo assessment of 11β-hydroxysteroid dehydrogenase type 1 activity by (19)F-Magnetic Resonance Spectroscopy

11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) amplifies tissue glucocorticoid levels and is a pharmaceutical target in diabetes and cognitive decline. Clinical translation of inhibitors is hampered by lack of in vivo pharmacodynamic biomarkers. Our goal was to monitor substrates and products of...

Descripción completa

Detalles Bibliográficos
Autores principales: Naredo-Gonzalez, Gregorio, Upreti, Rita, Jansen, Maurits A., Semple, Scott, Sutcliffe, Oliver B., Marshall, Ian, Walker, Brian R., Andrew, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523021/
https://www.ncbi.nlm.nih.gov/pubmed/36175417
http://dx.doi.org/10.1038/s41598-022-18740-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523021/
https://www.ncbi.nlm.nih.gov/pubmed/36175417
http://dx.doi.org/10.1038/s41598-022-18740-5

Ejemplares similares